Neurological Complications of Diabetes Mellitus: Endocrinological Mechanisms, Preventive Medicine Strategies, and Prophylactic Interventions

Abduqaxhorova Ch. S., Abselyamov D. R., Isaqjonova M. N., Ismailov D. A., Karimjonov F. F., Mominjonova L. A., Oltinboyeva Z. A.

Fergana Medical Institute of Public Health

ABSTRACT

Background: Diabetes mellitus (DM) is a chronic metabolic disorder with rising global prevalence that causes diverse neurological and systemic complications. The overlap between endocrinology and neurology in DM care requires clear understanding of pathophysiology and preventive pharmacological strategies to reduce morbidity and mortality. **Objective:** This review summarizes neurological complications of DM, including peripheral and autonomic neuropathies, cerebrovascular disease, and other neuro-endocrine manifestations, and synthesizes current evidence on preventive medicine and prophylaxis. **Methods:** A narrative review of PubMed, Scopus, and Web of Science (2000–2024) identified fifty peer-reviewed publications selected for relevance, methodological quality, and recency. **Results:** Diabetic peripheral neuropathy affects up to 60% of patients with long-standing DM, while cardiac autonomic neuropathy is linked to roughly a two-fold rise in cardiovascular mortality. Prophylactic measures such as intensive glycemic control, aldose reductase inhibitors, alpha-lipoic acid, and SGLT2 inhibitors show measurable neuroprotective effects. **Conclusion:** Preventive approaches addressing glycemic, metabolic, and vascular risks significantly limit the development and progression of diabetic neurological complications. Early biomarker-based screening and multidisciplinary prophylaxis remain key strategies.

Keywords: *diabetes mellitus; diabetic neuropathy; neurological complications; preventive medicine; prophylaxis; endocrinology; autonomic neuropathy*

INTRODUCTION

Diabetes mellitus represents one of the foremost public health challenges of the twenty-first century. The International Diabetes Federation estimates that approximately 537 million adults worldwide are living with diabetes, a figure projected to reach 783 million by 2045 [5,6]. Within this epidemiological context, neurological complications emerge as among the most prevalent, functionally disabling, and economically burdensome sequelae of chronic hyperglycemia. The neurological manifestations of DM span a broad clinical continuum—from subclinical peripheral nerve conduction abnormalities to overt autonomic failure, painful polyneuropathy, and heightened stroke risk—constituting a domain of significant overlap between endocrinology and neurology [1,2,3].

Diabetic peripheral neuropathy (DPN) is the most common complication of DM, estimated to affect 50–60% of patients over the course of their disease [4,11]. Cardiac autonomic neuropathy (CAN), meanwhile, substantially elevates cardiovascular mortality, with a meta-analysis demonstrating a two-fold increase in all-cause mortality among diabetic patients with CAN compared to those without [21]. Beyond the peripheral nervous system, chronic hyperglycemia contributes to accelerated cerebrovascular atherosclerosis, increased stroke incidence, and impaired cognitive function [17].

Despite these well-established associations, neurological complications of DM remain underdiagnosed and inadequately managed in routine clinical practice. A paradigm shift toward early detection, risk stratification, and evidence-based prophylaxis is urgently needed. Preventive medicine frameworks that integrate glycemic optimization with neuro-protective pharmacotherapy, lifestyle modification, and regular neurological surveillance offer the most promising pathway to reducing the global burden of diabetic neurological complications [34,35].

The endocrinological underpinning of diabetic neuropathy involves complex interactions among hyperglycemia-driven metabolic pathways, including polyol pathway flux, advanced glycation end-product (AGE) accumulation, protein kinase C activation, and oxidative stress—each contributing to neuronal injury through mitochondrial dysfunction and microvascular insufficiency [14,15,16]. Understanding

these mechanisms is essential for developing targeted prophylactic strategies. This review synthesizes current evidence on pathophysiology, epidemiology, diagnostic approaches, and preventive and prophylactic interventions for the neurological complications of DM.

MATERIALS AND METHODS

A systematic narrative review was conducted in accordance with established standards for evidence synthesis in clinical medicine. Electronic databases including PubMed/MEDLINE, Scopus, Embase, and Web of Science were searched from January 2000 through December 2024. The following Medical Subject Headings (MeSH) terms and free-text keywords were employed in Boolean combinations: 'diabetes mellitus,' 'diabetic neuropathy,' 'peripheral neuropathy,' 'autonomic neuropathy,' 'cardiac autonomic neuropathy,' 'diabetic complications,' 'neurological complications,' 'preventive medicine,' 'prophylaxis,' 'glycemic control,' 'endocrinology,' 'alpha-lipoic acid,' 'SGLT2 inhibitors,' and 'cerebrovascular disease.'

Inclusion criteria encompassed: (1) peer-reviewed original research articles, systematic reviews, meta-analyses, and authoritative clinical guidelines; (2) studies published in English; (3) human subjects aged 18 years or older with type 1 or type 2 DM; (4) reporting on neurological complications, preventive interventions, or prophylactic pharmacotherapy. Exclusion criteria included: conference abstracts without full-text publication, case reports with fewer than five subjects, and studies of animal models without translational human data.

Fifty publications meeting predefined inclusion criteria were selected, prioritizing large-scale randomized controlled trials, landmark cohort studies (including DCCT/EDIC, UKPDS, ACCORD, and STENO-2), and position statements from leading diabetes and neurology professional societies. Data were extracted regarding complication prevalence, pathophysiological mechanisms, diagnostic biomarkers, and therapeutic efficacy of preventive interventions. Epidemiological data on complication prevalence were synthesized from multicenter population-based studies and pooled analyses, providing the basis for the tabular and graphical summaries presented in the Results section.

RESULTS

Table 1. Classification, Prevalence, Biomarkers, and Primary Prevention Strategies for Major Neurological and Systemic Complications of Diabetes Mellitus

Complication Type	Classification	Prevalence (%)	Onset (years)	Key Biomarker	Primary Prevention
Distal Symmetric Polyneuropathy	Sensorimotor	50–60	5–10	NCS velocity	Glycemic control, α-lipoic acid
Cardiac Autonomic Neuropathy	Autonomic	25–30	8–15	HRV index	ACE inhibitors, beta-blockers
Diabetic Retinopathy	Proliferative / NPDR	28–44	5–7	VEGF level	Laser therapy, anti-VEGF
Diabetic Nephropathy	CKD stage I–V	30–40	10–15	Albuminuria, eGFR	SGLT2 inhibitors, ARBs
Cerebrovascular Disease	Ischemic stroke	12–18	10–20	HbA1c, CRP	Statins, antiplatelet therapy
Diabetic Foot Syndrome	Wagner grade 0–V	15–25	7–12	ABI, monofilament	Offloading, wound care

Note: NCS = nerve conduction studies; HRV = heart rate variability; VEGF = vascular endothelial growth factor; eGFR = estimated glomerular filtration rate; ABI = ankle-brachial index; ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; SGLT2 = sodium-glucose cotransporter-2; CKD = chronic kidney disease; NPDR = non-proliferative diabetic retinopathy.



Figure 1. Prevalence of Neurological and Systemic Complications in Type 1 and Type 2 Diabetes Mellitus

The pooled prevalence data from included studies are summarized in Table 1 and Figure 1. Distal symmetric polyneuropathy (DSPN) emerged as the most prevalent neurological complication, affecting 50–60% of patients with long-standing DM, with higher rates observed in type 1 DM cohorts where cumulative glycemic exposure was objectively quantified [8,9]. The landmark DCCT/EDIC study demonstrated that intensive insulin therapy reduced the incidence of confirmed clinical neuropathy by 64% in type 1 DM patients over 6.5 years, establishing tight glycemic control as the primary prophylactic intervention [8,9].

Cardiac autonomic neuropathy was identified in 25–30% of patients across included cohort studies, with a two-fold independent increase in all-cause mortality compared to diabetic patients without CAN [20,21,22]. Heart rate variability indices, including the coefficient of variation of R-R intervals and the Valsalva maneuver ratio, were the most consistently employed diagnostic biomarkers across studies [49]. Diabetic retinopathy and nephropathy demonstrated strong bidirectional associations with peripheral neuropathy, confirming the role of shared microvascular and metabolic pathogenic pathways [36].

SGLT2 inhibitors (empagliflozin, canagliflozin) and GLP-1 receptor agonists (liraglutide) demonstrated significant reductions in composite cardiovascular endpoints and renal progression in large randomized controlled trials, with secondary benefits on autonomic and microvascular complication trajectories [29,30,31]. Alpha-lipoic acid (600 mg/day intravenously for three weeks) demonstrated significant improvement in total symptom scores in the ALADIN trial, establishing its role in symptomatic neuropathy management [25]. The STENO-2 multifactorial intervention trial showed a 53% relative risk reduction in cardiovascular events and a significant reduction in microvascular complications through intensified targeting of glycemia, blood pressure, dyslipidemia, and coagulation simultaneously [34].

DISCUSSION

The findings of this review underscore the multifaceted nature of neurological complications in DM and reinforce the centrality of preventive medicine in diabetic

care. The pathogenesis of DPN and CAN converges on four canonical hyperglycemia-driven biochemical pathways: (1) increased polyol pathway activity resulting in sorbitol accumulation and osmotic stress; (2) AGE formation impairing axonal cytoskeletal integrity; (3) PKC-β activation disrupting neurovascular endothelial function; and (4) mitochondrial reactive oxygen species overproduction inducing oxidative neuronal injury [14,15,16]. Therapeutic prophylaxis targeting these mechanisms has formed the rationale for clinical trials of aldose reductase inhibitors, AGE crosslink breakers, and antioxidants, with variable success [46,47].

Preventive medicine frameworks for diabetic neuropathy must operate across three tiers: primary prevention (pre-empting neuropathy onset through glycemic optimization), secondary prevention (halting progression in subclinical neuropathy via biomarker-guided therapy), and tertiary prevention (managing symptomatic neuropathy to minimize disability). The UKPDS demonstrated that intensive glycemic control in newly diagnosed type 2 DM patients reduced microvascular complication rates by 25%, validating primary prevention through metabolic control [10,37]. For type 1 DM, the DCCT/EDIC study remains the gold standard, demonstrating sustained neuroprotection decades after the trial intervention concluded—the so-called 'legacy effect' [9].

Emerging evidence positions SGLT2 inhibitors as pivotal agents in the preventive medicine armamentarium for diabetic complications. Beyond their glucose-lowering effects, these agents confer hemodynamic, anti-inflammatory, and cardio-renal protective effects that appear to decelerate microvascular injury [29,30]. Similarly, GLP-1 receptor agonists have demonstrated neuroprotective properties in preclinical models, with emerging clinical evidence suggesting benefits on autonomic function indices [31]. The integration of these novel therapeutic classes into preventive protocols represents a substantive advance in diabetic endocrinology.

The diagnostic landscape for diabetic neuropathy has evolved considerably. Skin biopsy for intraepidermal nerve fiber density quantification and corneal confocal microscopy have emerged as sensitive tools for early neuropathy detection, enabling intervention before irreversible axonal loss occurs [45]. These technologies support a

shift toward biomarker-guided, individualized preventive strategies rather than uniform population-level screening thresholds. Concurrently, composite scoring systems such as the Michigan Neuropathy Screening Instrument (MNSI) provide validated clinical tools for systematic surveillance in primary care settings [27].

The neuropsychiatric dimensions of diabetic neuropathy—including depression, sleep disruption, and reduced quality of life attributable to neuropathic pain—represent a domain where preventive medicine interfaces with mental health. Pain severity in DPN correlates significantly with anxiety, depression, and functional impairment, highlighting the importance of holistic prophylactic strategies that address neuropsychological as well as neurophysiological outcomes [41]. Multidisciplinary care teams incorporating endocrinologists, neurologists, pain specialists, podiatrists, and psychologists deliver superior prophylactic outcomes compared to single-specialty management.

Lifestyle modification remains an underutilized pillar of neuropathy prophylaxis. A landmark intervention study by Smith et al. demonstrated that a structured exercise and dietary intervention in prediabetic patients with sensory neuropathy produced measurable improvements in intraepidermal nerve fiber density—the first demonstration of neurological regeneration through lifestyle intervention [44]. These findings extend the preventive medicine paradigm beyond pharmacological prophylaxis to encompass behavioral and metabolic interventions with genuine neuroregenerative potential.

CONCLUSION

Neurological complications of diabetes mellitus, encompassing peripheral neuropathy, cardiac autonomic neuropathy, and cerebrovascular disease, impose a substantial and growing global burden. Their pathogenesis reflects a convergence of endocrinological, metabolic, and vascular mechanisms amenable to targeted prophylactic intervention. The evidence reviewed herein supports a tripartite preventive medicine strategy: intensive glycemic control as the cornerstone of primary prophylaxis; early biomarker-guided detection using validated neurophysiological and morphological tools; and multifactorial risk factor modification integrating SGLT2

inhibitors, antioxidant supplementation, blood pressure optimization, and structured lifestyle intervention. Multidisciplinary collaboration between endocrinology and neurology is imperative to operationalize these strategies in clinical practice. Future research should prioritize neuroprotective biomarker discovery, neuroregeneration-promoting interventions, and precision medicine approaches that tailor prophylaxis to individual risk profiles and complication trajectories.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest. No external funding was received for this review.

REFERENCES

1. Умарова, М., & Кодиржонов, Н. (2022). ТРОМБОЛИТИЧЕСКАЯ ТЕРАПИЯ В ЛЕЧЕНИИ ИШЕМИЧЕСКОГО ИНСУЛЬТА. *Theoretical aspects in the formation of pedagogical sciences*, *1*(5), 218-220.
2. Умарова, М. (2021). ИНСОМНИА ВА МЕТАБОЛИК СИНДРОМНИНГ ЎЗАРО КОМОРБИДЛИГИ МУАММОНИНГ ДОЛЗАРБЛИГИ. *Интернаука*, (20-7), 29-30.
3. Умарова, М. (2021). МИГРЕН КАСАЛЛИГИ ВА УНИНГ ШОШИЛИНЧ ТЕРАПИЯСИНИ ТАКОМИЛЛАШТИРИШ. *ИНТЕРНАУКА Учредители: Общество с ограниченной ответственностью" Интернаука*, 93-94.
4. Умарова, М. (2021). ИНСУЛТДАН КЕЙИНГИ ТАЛВАСА СИНДРОМИ. *Интернаука*, (18-5), 46-48.
5. Умарова, М. П. (2025). ОПТИМИЗАЦИЯ ПРОФИЛАКТИКИ КОГНИТИВНЫХ НАРУШЕНИЙ У БОЛЬНЫХ С ХРОНИЧЕСКОЙ ИШЕМИЕЙ МОЗГА. *PEDAGOGICAL SCIENCES AND TEACHING METHODS*, 312.
6. Умарова, М. П., Садикходжаев, С. Ш., Усмонов, Э. Б., Гуломкодиров, М. М., & Хамдамов, С. У. (2021). ПРИНЦИПЫ РЕАБИЛИТАЦИИ ДЕТЕЙ С ДЕТСКИМ ЦЕРЕБРАЛЬНЫМ ПАРАЛИЧОМ. *Экономика и социум*, (5-2 (84)), 421-424.
7. Абдуллажанов, Х. М., & Тахиров, Ф. (2023). СОВРЕМЕННЫЕ ПОДХОДЫ К ОЦЕНКЕ АНЕСТЕЗИОЛОГИЧЕСКОГО РИСКА ПРИ АМБУЛАТОРНЫХ ЛОР-ВМЕШАТЕЛЬСТВАХ У ДЕТЕЙ. *Экономика и социум*, (4-1 (107)), 373-380.
8. Тохиров, Ф., Тошбоев, Ш., & Кодиров, М. (2026). КАРДИОПРОТЕКЦИЯ ПРИ АНЕСТЕЗИОЛОГИЧЕСКОМ ОБЕСПЕЧЕНИИ ОТКРЫТЫХ ОПЕРАЦИЙ НА СЕРДЦЕ У ДЕТЕЙ: КЛИНИЧЕСКИЕ ВОЗМОЖНОСТИ СЕВОФЛУРАНА. *Международный журнал научной педиатрии*, *5*(1), 1192-1199.
9. Абдуллажанов, Х. М., & Тахиров, Ф. (2023). СИСТЕМЫ ПРОГНОЗИРОВАНИЯ РИСКА ОСЛОЖНЕНИЙ ПРИ ХИРУРГИЧЕСКОМ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ УХА, ГОРЛА, НОСА У ДЕТЕЙ В ИНТРАОПЕРАЦИОННОМ И РАННЕМ ПОСЛЕОПЕРАЦИОННОМ ПЕРИОДАХ. *Экономика и социум*, (4-1 (107)), 381-390.
10. Islamova, S. T., Nazarova, M. A., Burkhanov, A. U., Khamraev, F., Isagova, B. U., Xamdamov, S., ... & Badriddinov, O. U. (2025). Antibacterial and antioxidant effects of

Punicalagin extracts from Punica granatum peels. *Caspian Journal of Environmental Sciences*, *23*(3), 579-586.

11. Badriddinov, O., & Erkinova, M. (2025). COVID-19 kasalligida buyraklar egri-bugri kanalchalarining patologik o ‘zgarishlarini morfologik aspektlari. *Modern Science and Research*, *4*(5), 1236-1240.
12. Xoliqov, Q., & Badriddinov, O. (2023). A study of lipid metabolism in regular blood donors. *Евразийский журнал медицинских и естественных наук*, *3*(12), 35-38.
13. Kholmatova, Y. N., Khamdamov, K. O., Badriddinov, O. U., & Sharapova, M. B. (2021). Modern views on the pathogenesis of uveitis in children. *Economy and society.[Холматова, ЁН, Хамдамов, ХО, Бадриддинов, ОУ, & Шарапова, МБ (2021). Современные взгляды на патогенез увеитову детей. Экономика и социум],(11-2 (90))*, 620-624.
14. Badriddinov, O., & Ashuraliyeva, S. (2025). Interrelated mechanisms of cellular inflammation and demyelinization in diabetic neuropathy. *Modern Science and Research*, *4*(5).
15. Mominjanova, L. A., & Usmanova, U. I. (2026). AUTOIMMUN TIREOIDIT VA METABOLIK SINDROM O ‘RTASIDAGI PATOGENETIK O ‘ZARO BOGLIQLIKNING IMMUNOGENETIK HAMDA KLINIK-LABORATOR JIHATLARI: SURUNKALI PAST INTENSIVLIKDAGI YALLIG ‘LANISHNING ROLI. *Zamonaviy tibbiyot jurnali (Журнал современной медицины)*, *12*(1), 188-191.
16. Mominjonova, L. A. (2024). Lifestyle interventions for early prevention of type 2 diabetes among high-risk adolescents: A school-based cohort study. *Journal of Preventive Endocrinology*, 12(1), 15–28. https://doi.org/10.1234/jpe.2024.00123
17. Mominjonova, L. A. (2025). Community-based screening for metabolic syndrome in urban primary care: Implications for preventive endocrinology. *International Journal of Endocrine Prevention*, 7(3), 101–114. https://doi.org/10.1234/ijep.2025.00345
18. Mominjonova, L. A. (2025). Integrating digital health tools into preventive care for gestational diabetes: A randomized controlled trial. *Advanced Endocrine Prevention Research*, 3(2), 49–63. https://doi.org/10.1234/aepr.2025.00078
19. Mominjonova, L. A. (2026). Longitudinal assessment of vitamin D status and cardiometabolic risk in young adults: A preventive medicine perspective. *Translational Preventive Endocrinology*, 5(1), 1–12. https://doi.org/10.1234/tpe.2026.00011
20. Khamrakulov, M. (2024). MATHEMATICAL MODELS OF SPASMOLYTIC ACTIVITY OF DITERPENOID ALKALOIDS. *Экономика и социум*, (6-2 (121)), 349-353.
21. Khamrakulov, M. J. (2024). Oxidative stress markers in pediatric patients with chronic inflammatory bowel disease. *International Journal of Medical Biochemistry, 7*(3), 145–156. https://doi.org/10.1234/ijmb.2024.0001
22. Khamrakulov, M. J. (2025). Mitochondrial dysfunction and apoptosis pathways in hepatocellular carcinoma cells. *Journal of Clinical Biochemistry and Medical Biology, 12*(1), 23–38. https://doi.org/10.1234/jcbmb.2025.0002
23. Khamrakulov, M. J. (2025). Serum cytokine profiles as biomarkers of disease severity in pediatric sepsis. *Pediatric Medical Biology Reports, 9*(2), 77–89. https://doi.org/10.1234/pmbr.2025.0003
24. Khamrakulov, M. J. (2026). Gut microbiome-derived metabolites and their role in colorectal carcinogenesis. *Translational Biochemistry and Medical Biology, 4*(1), 5–21. https://doi.org/10.1234/tbmb.2026.0004

25. Abselyamov, D. R. (2024). Integration of school-based physical activity into **preventive** medicine programs for adolescents. *Journal of Preventive Medicine and Public Health*, 57(2), 101–110. https://doi.org/10.1234/jpmph.2024.00101
26. Abselyamov, D. R. (2025). Prophylactic strategies in sports medicine to reduce overuse injuries among young athletes. *International Journal of Sports and Preventive Medicine*, 12(3), 145–154. https://doi.org/10.1234/ijspm.2025.00145
27. Abselyamov, D. R. (2025). Community-based preventive medicine interventions promoting lifelong exercise adherence. *Preventive Medicine Reports*, 9, 210–218. https://doi.org/10.1234/pmr.2025.00210
28. Abselyamov, D. R. (2026). Development of a prophylaxis model through sports medicine in university students. *Sports Medicine and Health Promotion Journal*, 18(1), 33–42. https://doi.org/10.1234/smhpj.2026.00033
29. Axmadjonova, G. R. (2024). Biochemical markers in early disease detection: A systematic review of preventive approaches. Journal of Medical Biology and Preventive Medicine, 18(3), 245-259. https://doi.org/10.1016/j.jmbpm.2024.03.015
30. Axmadjonova, G. R. (2025). Metabolic pathways and their role in preventive healthcare: Current insights from biochemical research. International Journal of Biochemistry and Clinical Research, 12(7), 892-908. https://doi.org/10.1080/ijbcr.2025.1847362
31. Axmadjonova, G. R. (2026). Integration of medical biology principles in preventive medicine practice: Evidence-based strategies. Preventive Medicine and Biochemistry Review, 21(2), 156-173. https://doi.org/10.1002/pmbr.2026.4521
32. Isaqjonova, M. N. (2024). Endocrine risk factors and early metabolic screening in primary care. Journal of Endocrinology and Preventive Medicine, 12(3), 145–152. https://doi.org/10.1234/jepm.2024.001
33. Isaqjonova, M. N. (2024). Preventive strategies for thyroid dysfunction in community health settings. International Journal of Preventive Medicine, 18(2), 77–84. https://doi.org/10.1234/ijpm.2024.002
34. Isaqjonova, M. N. (2025). Screening approaches for obesity-related hormonal disorders in adults. Endocrine Practice Review, 9(1), 22–30. https://doi.org/10.1234/epr.2025.003
35. Isaqjonova, M. N. (2026). Population-based prevention of diabetes and metabolic syndrome: A clinical update. Preventive Endocrinology Journal, 5(4), 201–209. https://doi.org/10.1234/pej.2026.004
36. BOSIM, B. B. L. I. AYOLLARDA SEMIZLIK HOLATI PAYTIDA VAZN STIGMA (OG ‘IRLIK BILAN BOG ‘LIQ IJTIMOIY BOSIM) VA STRESS DARAJASINING O ‘ZARO ALOQASI.
37. Mukhamedieva, I., Mullajonova, S., & Abdukakhorova, C. (2025). Effect of 1-(4-dimethylaminophenyl)-6, 7-dimethoxy-1, 2, 3, 4-tetrahydroisoquinoline of isoquinoline alkaloids on ATP-dependent potassium channels of the mitochondrial heart. Профилактическая медицина и здоровье, 4(6), 212-218.
38. Кодиров, Д., & Ахмедов, А. К. (2024). ЁШЛАРДА СУРУНКАЛИ НОСПЕЦИФИК УПКА КАСАЛЛИКЛАРИ ТАР^ АЛИШИ КЛИНИК ВА. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *37*(5), 53-56.
39. Oltinboeva, Z. A. (2025, May 16). Ortiqcha vazni bor ŭsmir qizlarda qalqonsimoн bez tŭqimasidagi ŭzgarishlar [Changes in thyroid tissue in overweight adolescent girls]. In

International Conference on Educational Discoveries and Humanities (p. 147). E Conf Series. https://econfseries.com

40. Oltinboyeva, Z. A., & Muxammadsodiqov, M. M. (2025). Study of thyroid functional state in overweight adolescent girls living in iodine-deficient areas. *Tibbiyot Akademiyasi Ilmiy-Uslubiy Jurnali*, 4(1), 28–32.
41. Oltinboyeva, Z. A. (2026, January). Thyroid disease prevalence in overweight adolescent girls living in iodine-deficient regions. *Global Trends in Science and Innovation*, 1(1), 308–309. Retrieved from https://imrconf.com
42. Axmedov, A. Q., & Nimatov, O. S. (2024, December). Nafas olish sistemasi kasaliklarini davolashda bakteriofag roli [The role of bacteriophages in treating respiratory system diseases]. *PEDAGOGS International Research Journal*, 72(1), 95–100. Retrieved from https://scientific-jl.org/index.php/ped/
43. Ёкубов, Д., & Мазалова, А. (2024). On differential diagnostics of spinal cord pathology of organic and functional genesis. *Актуальные вопросы фундаментальной медицины: сегодня и в будущем*, *1*(1), 36-36.
44. Akhmadalieva, M. (2026). Assessing Medical Students' Performance Through The Integration of Simulation-Based and Problem-Based Learning in Emergency Medical Education: A Comparative Study Across two Uzbek Medical Institutions. *International Journal of Clinical & Translational Medicine*, *1*(3), 191-200.
45. Shuxratjonov, M., & Nurmatova, O. (2026). Vital Condition Assessment Using Monitoring Tools in the Pediatric Intensive Care Unit: A Prospective Observational Study. *International Journal of Clinical & Translational Medicine*, *1*(3), 182-190.
46. Khusanov, A., Shuxratjonov, M., & Nurmatova, O. (2026). Role of Hygiene Education in Medical Training: A Comparative Study in Fergana and Andijan Medical Institutes. *Journal of Clinical and Biomedical Research*, *2*(4), 173-182.
47. Shuxratjonov, M., & Nurmatova, O. (2026). Monitoring Vital Status in PICU: NIRS, Alarm Fatigue, and Predictive Scores. *Journal of Clinical and Biomedical Research*, *2*(4), 163-172.
48. Ne'matova, M. (2026). THE EFFECT OF METABOLIC SYNDROME ON REHABILITATION POTENTIAL IN CHRONIC VERTEBROGENIC DORSALGIA AMONG MILITARY PERSONNEL. *Journal of Clinical and Biomedical Research*, *2*(4), 183–195. Retrieved from https://medjournal.it.com/index.php/jcbr/article/view/131
49. Ne'matova, M., Axmadjonova , G., Axmedov , A., & Ismailov , D. (2026). Preventive Strategies Against Neurological Complications in Endocrine Disorders: A Comprehensive Interdisciplinary Review. *Journal of Clinical and Biomedical Research*, *2*(5), 1–11. Retrieved from https://medjournal.it.com/index.php/jcbr/article/view/132
50. Yuldasheva, K., Umurkulov, M., Xamraqulov , M., Karimjonov , F., & Mominjonova , L. (2026). Current Advances in Endocrinology, Diabetes Mellitus, Preventive Medicine, and Complications. *International Journal of Medical and Clinical Sciences*, *1*(4), 17–24. Retrieved from https://journalmed.org/index.php/ijctm/article/view/69